PEDRO PIEDRA to Administration, Inhalation
This is a "connection" page, showing publications PEDRO PIEDRA has written about Administration, Inhalation.
Connection Strength
0.125
-
Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021 01; 9(1):21-32.
Score: 0.041
-
Marked variability observed in inpatient management of bronchiolitis in three Finnish hospitals. Acta Paediatr. 2017 Sep; 106(9):1512-1518.
Score: 0.033
-
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016 01; 60(1):6-13.
Score: 0.029
-
Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 1995 Sep; 16(3):393-9.
Score: 0.007
-
High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J Pediatr. 1990 Aug; 117(2 Pt 1):313-20.
Score: 0.005
-
Effect of respiratory syncytial virus infection on the uptake of and immune response to other inhaled antigens. Proc Soc Exp Biol Med. 1988 Jun; 188(2):191-7.
Score: 0.004
-
Modulation of systemic and mucosal immune responses to inhaled ragweed antigen in experimentally induced infection with respiratory syncytial virus implication in virally induced allergy. Int Arch Allergy Appl Immunol. 1988; 86(1):112-6.
Score: 0.004